Kidney shield: diabetes Drug's hidden powers revealed?
NCT ID NCT05507892
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how canagliflozin (Invokana), a diabetes drug, protects the kidneys in people with type 2 diabetes. Researchers will use advanced imaging, kidney biopsies, and function tests to uncover the mechanisms. The trial involves 45 adults and aims to explain the drug's kidney-protective effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
canagliflozin (Invokana)
What this could lead to
If successful, this could reveal exactly how canagliflozin protects the kidneys, potentially leading to better treatments for diabetic kidney disease.
What could go wrong
This is a small, early-phase study focused on understanding mechanisms, not proving clinical benefit. Results may not lead to new treatments or apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Colorado Denver
Aurora, Colorado, 80045, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States